Susceptibility of Escherichia coli from community-acquired urinary tract infection to fosfomycin, nitrofurantoin, and temocillin in Korea

Journal of Korean Medical Science

Volumn 29, Issue 8, 2014, Pages 1178-1181

  Seo, Mi Ran ^a   Kim, Seong Jong ^a   Kim, Yeonjae ^a   Kim, Jieun ^a   Choi, Tae Yeal ^a   Kang, Jung Oak ^a   Wie, Seong Heon ^b   Ki, Moran ^c   Cho, Young Kyun ^d   Lim, Seung Kwan ^e   Lee, Jin Seo ^f   Kwon, Ki Tae ^g   Lee, Hyuck ^h   Cheong, Hee Jin ⁱ   Park, Dae Won ^j   Ryu, Seong Yeol ^k   Chung, Moon Hyun ^l   Pai, Hyunjoo ^a  

^a Hanyang University   (South Korea)

^b The Catholic University of Korea   (South Korea)

^c Eulji University School of Medicine   (South Korea)

^d Gachon University   (South Korea)

^e Ajou University Medical CentSuwon   (South Korea)

^f Hallym University   (South Korea)

^g Department of Internal Medicine   (South Korea)

^h Dong A University College of Medicine   (South Korea)

ⁱ Korea University College of Medicine   (South Korea)

^j Korea University   (South Korea)

^k Dongsan Medical Center   (South Korea)

^l Inha University Hospital   (South Korea)

more..

Author keywords

Cefepime; Ciprofloxacin; Community acquired infections; Escherichia coli; Fosfomycin; Minimal inhibitory concentration; Nitrofurantoin; Temocillin; Trimethoprim sulfamethoxazole combination; Urinary tract

Indexed keywords

ANTIINFECTIVE AGENT; CEFEPIME; CEPHALOSPORIN DERIVATIVE; CIPROFLOXACIN; DRUG COMBINATION; FOSFOMYCIN; NITROFURANTOIN; PENICILLIN DERIVATIVE; SULFADOXINE; TEMOCILLIN; TRIMETHOPRIM; TRIMETHOPRIM, SULFADOXINE DRUG COMBINATION;

ANTIBIOTIC RESISTANCE; CELL SURVIVAL; COMMUNITY-ACQUIRED INFECTIONS; DOSE RESPONSE; DRUG COMBINATION; DRUG EFFECTS; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTIONS; HUMAN; MICROBIOLOGY; SOUTH KOREA; TREATMENT OUTCOME; URINARY TRACT INFECTIONS;

ANTI-BACTERIAL AGENTS; CELL SURVIVAL; CEPHALOSPORINS; CIPROFLOXACIN; COMMUNITY-ACQUIRED INFECTIONS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG COMBINATIONS; DRUG RESISTANCE, BACTERIAL; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTIONS; FOSFOMYCIN; HUMANS; NITROFURANTOIN; PENICILLINS; REPUBLIC OF KOREA; SULFADOXINE; TREATMENT OUTCOME; TRIMETHOPRIM; URINARY TRACT INFECTIONS;

EID: 84910023053     PISSN: 10118934     EISSN: 15986357     Source Type: Journal    
DOI: 10.3346/jkms.2014.29.8.1178     Document Type: Article

References (12)

1. Lee SJ, Lee DS, Choe HS, Shim BS, Kim CS, Kim ME, Cho YH. Antimicrobial resistance in community-acquired urinary tract infections: results from the Korean Antimicrobial Resistance Monitoring System. J Infect Chemother 2011; 17: 440-6.
2. Hooton TM. Fluoroquinolones and resistance in the treatment of uncomplicated urinary tract infection. Int J Antimicrob Agents 2003; 22: 65-72.
3. Lee MY, Choi HJ, Choi JY, Song M, Song Y, Kim SW, Chang HH, Jung SI, Kim YS, Ki HK, et al. Dissemination of ST131 and ST393 community-onset, ciprofloxacin-resistant Escherichia coli clones causing urinary tract infections in Korea. J Infect 2010; 60: 146-53.
4. Garau J. Other antimicrobials of interest in the era of extended-spectrum beta-lactamases: fosfomycin, nitrofurantoin and tigecycline. Clin Microbiol Infect 2008; 14: 198-202.
5. Ko KS, Suh JY, Peck KR, Lee MY, Oh WS, Kwon KT, Jung DS, Lee NY, Song JH. In vitro activity of fosfomycin against ciprofloxacin-resistant or extended-spectrum beta-lactamase-producing Escherichia coli isolated from urine and blood. Diagn Microbiol Infect Dis 2007; 58: 111-5.
6. Kim KY, Kim CS, Lim DH. The ciprofloxacin resistance pattern of Escherichia coli isolated from female patients with community - acquired urinary tract infection in the Jeonnam and Gwangju region for the recent 2-years. Korean J Urol 2008; 49: 540-8.
7. Lee SY, Park YJ, Yu JK, Jung S, Kim Y, Jeong SH, Arakawa Y. Prevalence of acquired fosfomycin resistance among extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae clinical isolates in Korea and IS26-composite transposon surrounding fosA3. J Antimicrob Chemother 2012; 67: 2843-7.
8. Clinical and Laboratory Standard Institute. Performance standards for antimicrobial susceptibility testing: 15th informational supplement: CLSI document M100-S15. Wayne: CLSI, 2005. Available at http://clsi.crg [accessed on 1 January 2005].
9. Kim B, Kim J, Wie SH, Park SH, Cho YK, Lim SK, Shin SY, Yum JS, Lee JS, Kweon KT, et al. Is it acceptable to select antibiotics for the treatment of community-acquired acute cystitis based on the antibiotics susceptibility results for uropathogens from community-acquired acute pyelonephritis in Korea? Infect Chemother 2012; 44: 269-74.
10. Balakrishnan I, Awad-El-Kariem FM, Aali A, Kumari P, Mulla R, Tan B, Brudney D, Ladenheim D, Ghazy A, Khan I, et al. Temocillin use in England: clinical and microbiological efficacies in infections caused by extended-spectrum and/or derepressed AmpC β-lactamase-producing Enterobacteriaceae. J Antimicrob Chemother 2011; 66: 2628-31.
11. Livermore DM, Warner M, Mushtaq S, Doumith M, Zhang J, Woodford N. What remains against carbapenem-resistant Enterobacteriaceae? evaluation of chloramphenicol, ciprofloxacin, colistin, fosfomycin, minocycline, nitrofurantoin, temocillin and tigecycline. Int J Antimicrob Agents 2011; 37: 415-9.
12. Andrews JM, Howe RA; BSAC Working Party on Susceptibility Testing. BSAC standardized disc susceptibility testing method (version 10). J Antimicrob Chemother 2011; 66: 2726-57.